Invion Ltd. · ASX:IVX
Invion — 11th Annual Australian Microcap Investment Conference (October 2022)
21 slides from Invion's conference presentation, Oct 18, 2022
Slide 1: Invion Conference Presentation ASX Announcement
ASX ANNOUNCEMENT INVION CONFERENCE PRESENTATION For personal use only MELBOURNE (AUSTRALIA) 18 October 2022: Invion Limited (ASX: IVX) (“Invion” or the “Company”) will be presenting at the 11th Annual Australian Microcap Investment Conference today at 11.45 am. Invion’s Executive Chairman and Chief
Slide 2: Investor Presentation October 2022
For personal use only INVESTOR PRESENTATION October 2022
Slide 3: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p
Slide 4: Company Overview: Developing the Next-Gen Photodynamic Therapy
COMPANY OVERVIEW DEVELOPING THE NEXT-GEN PHOTODYNAMIC THERAPY (PDT) For personal use only Major disease areas: Cancer + atherosclerosis and infectious diseases (AID) Meeting Clinical Advancing Photosoft™ technology – novel PDT photosensitiser INV043 Needs Collaboration with world-class experti
Slide 5: The Photosoft Advantage: A Novel Cancer Treatment
THE PHOTOSOFTTM ADVANTAGE A NOVEL CANCER TREATMENT For personal use only NGPDT (Next-Gen PDT) is a ground-breaking NGPDT is a minimally invasive modality for technology that overcomes many of the treating cancer that specifically identifies and shortcomings of early PDT technologies and destroys can
Slide 6: Lead Cancer Drug Candidate INV043
LEAD CANCER DRUG CANDIDATE INV043 PATHWAY TO A US$271B MARKET OPPORTUNITY1 For personal use only Proof-of-Concept studies of lead candidate INV043 has been shown to: Selectively absorbed by cancer cells and not healthy tissue Invion is leading the Effective in regressing multiple types of cancer in
Slide 7: Key Partnerships: World-Leading Institutions
KEY PARTNERSHIPS WORLD-LEADING INSTITUTIONS For personal use only • Global bioscience medical research institute • World-class institute that combines its premier • Over 400 scientists focused on ground-breaking cancer research capability with its ability to discoveries addressing complex problems i
Slide 8: Cancer Findings
For personal use only Cancer Findings Proof-of-Concept Studies on INV043
Slide 9: Improved API: INV043 Key Characteristics
IMPROVED API: INV043 KEY CHARACTERISTICS* For personal use only Active against multiple cancers Highly potent and selective INV034 activity against multiple cancer cell types • INV043 successfully regressed • ~600x greater photoxicity established T-cell lymphoma, than Talaporfin sodium (a triple neg
Slide 10: Proof of Concept: Primary Tumour Pilot Study
PROOF OF CONCEPT: PRIMARY TUMOUR PILOT STUDY REGRESSION AND PROTECTIVE IMMUNITY For personal use only Treatment with established tumours (INV043 with light) • INV043 was injected intratumorally (0.1mg/kg) • 16 hours later, illuminated with red light • No anaesthesia required, no adverse effects obse
Slide 11: Proof of Concept: Primary Tumour Pilot Study
PROOF OF CONCEPT: PRIMARY TUMOUR PILOT STUDY REGRESSION AND PROTECTIVE IMMUNITY For personal use only • Triple Negative Breast Cancer (TNBC) is a hard-to-treat cancer resistant to most chemotherapies • Proof of Concept (PoC) pilot showed complete regression of TNBC in vivo following INV043 treatment
Slide 12: Anal Cancer SCC: Promising Results Against New Cancer Class
ANAL CANCER SCC PROMISING RESULTS AGAINST NEW CANCER CLASS* For personal use only Cytotoxicity data of human anal SCC cells lines In vitro study showed INV043’s effectiveness against six squamous cell carcinoma (SCC) cell lines that represent the full range of anal cancers Most anal cancers are SCCs
Slide 13: Proof of Concept: Immune Checkpoint Inhibitors Combination Therapy
PROOF OF CONCEPT: IMMUNE CHECKPOINT INHIBITORS (ICI) COMBINATION THERAPY FOR A US$140B MARKET1 (BY 2030) For personal use only • Immune checkpoint inhibitors are widely used for the treatment of lung cancer and melanoma. However, ICI treatments are typically only effective on a small proportion of p
Slide 14: Infectious Diseases Findings
For personal use only Infectious Diseases Findings In Vitro Studies on Infectious Diseases
Slide 15: Effective Against SARS-CoV-2 In Vitro
EFFECTIVE AGAINST SARS-CoV-2 IN VITRO ANTIVIRAL ACTIVITY AGAINST DELTA AND OMICRON VARIANTS For personal use only Selected PhotosoftTM Compounds vs. Remdesivir - Delta 100 Nine out of ten PhotosoftTM compounds tested 80 % Inhibition displayed antiviral activity against both Delta 60 and Omicron vari
Slide 16: Effective Against Zika In Vitro
EFFECTIVE AGAINST ZIKA IN VITRO ANTIVIRAL ACTIVITY AGAINST ZIKA For personal use only Example of a PhotosoftTM compound vs Monensin 100 Percentage (%) inhibition 90 80 70 60 % Inhibition - PhotosoftTM compound 50 40 % Cytotoxicity - PhotosoftTM compound 30 % Inhibition - Monensin 20 10 % Cytotoxicit
Slide 17: The Way Forward: Multiple Catalysts and Milestones
THE WAY FORWARD MULTIPLE CATALYSTS AND MILESTONES For personal use only Australia • Proof of Concept (PoC) Building on in vivo work further demonstrating both safety and efficacy profiles • Pre-clinical Preparations: Building foundations for clinical trials in multiple indications and internationall
Slide 18: Management Team
MANAGEMENT TEAM THE RIGHT EXPERTISE FOR SUCCESS For personal use only THIAN CHEW MELANIE LEYDIN EXECUTIVE CHAIRMAN & CEO CFO • Managing Partner, Polar Ventures • 25+ years in accounting profession • Executive Director, Goldman Sachs • Partner, Vistra • Director, KPMG Consulting, Senior Manager KPMG
Slide 19: Summary
SUMMARY For personal use only Cancer - Promising Results: Infectious Diseases – Early Findings: Total tumour regression, In vitro effectiveness against multiple immune response, potential ICI viruses including SARS-CoV-2 (Delta combination therapies and Omicron) as well as Zika Cancer - Clinical Tri
Slide 20: Market Overview
YTD Share Price* MARKET OVERVIEW $0.012 For personal use only (as of 03 Oct 2022) Market Cap A$77m Clinical-stage life sciences TOP 10 SHAREHOLDERS %IC company developing the Focus PhotosoftTM technology as Polar Ventures Limited 8.49 a treatment for a range of BNP Paribas Nominees Pty Ltd 7.99 dise
Slide 21: For personal use only
For personal use only
Invion — 11th Annual Australian Microcap Investment Conference (October 2022) on 6ix